Journal: iScience

Article Title: Proteogenomic characterization of pancreatic neuroendocrine tumors uncovers hypoxia and immune signatures in clinically aggressive subtypes

doi: 10.1016/j.isci.2024.110544

Figure Lengend Snippet:

Article Snippet: Rabbit monoclonal anti-p-mTOR (dilution 1:200) , Cell Signaling , Cat. # 2976; RRID: AB_490932.

Techniques: Recombinant, Software

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

doi: 10.1186/s13046-019-1121-3

Figure Lengend Snippet: Phosphorylated mTOR expression is a prognostic marker for diffuse-type GC patients, and Wnt-mTOR axis is involved in the growth regulation of diffuse-type GC-initiating cells. a , c Representative immunohistochemical micrographs of phosphorylated mTOR expressions in primary intestinal-type ( a ) and diffuse-type ( c ) GC tissues. b , d Kaplan-Meier analyses of overall survival for non-diffuse-type ( b ) and diffuse-type ( d ) GC patients with phosphorylated mTOR expression. Diffuse-type GC patients with strong phosphorylated mTOR expression (solid red line) had a significant poorer outcome than those with weak phosphorylated mTOR expression (dotted blue line) ( P = 0.044), while no significant differences were found between the two in non-diffuse type GC patients. e Wnt-mTOR axis is involved in the growth regulation of diffuse-type GC-initiating cells. Results on effects of temsirolimus, Wnt3a, R-spondin-1, CHIR99021, and FH535 on the growth of diffuse- and intestinal-type GC-initiating cells in primary culture, shown in Additional file : Figure S9, and Figures S11 to S14 are summarized. Significant growth stimulation is shown by upward arrows, while significant growth suppression by downward arrows, respectively (no significant changes by horizontal arrows). Strong (more than 151%) growth stimulations are shown by purple, and strong (less than 66%) and weak (67–100%) growth suppressions are shown by blue and light blue, respectively (no significant changes by light gray)

Article Snippet: Expression of phosphorylated-mTOR (p-mTOR) was examined by using anti-p-mTOR rabbit monoclonal antibody (clone 49F9) from Cell Signaling Technology, and Ventana BenchMark XT automatic immunostainer systems.

Techniques: Expressing, Marker, Immunohistochemical staining

Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

doi: 10.1186/s13046-019-1121-3

Figure Lengend Snippet: PD-L1 expression in GCs, and estimation of responders to immune checkpoint inhibitors and mTOR inhibitors in patients with various GCs. a Light micrographs showing PD-L1 expressions in intestinal- and diffuse-type GCs. An area shown by a square in the diffuse-type GC is enlarged on the right. b The relationship between PD-L1 and mTOR expressions in diffuse-type GCs. A significant difference was found between PD-L1-positive and -negative patients on the expression of mTOR. *** P < 0.001 by Chi-square test between two populations. c The ratio of PD-L1-positive cells in whole (attached + easily-detached), attached, and easily-detached cell fractions in HGC-3 and -20 cells. Percentages of PD-L1-positive cells in the rectangle in the left figures were determined, and compared. Mean ± SD of five independent experiments. * P < 0.05 by two sample t-test. d Estimation of responders to immune checkpoint inhibitors and mTOR inhibitors in patients with various GCs. Since all PIK3CA mutated GCs were EBV or MSI subtypes in TCGA cohort, and all patients with EBV or MSI subtype GC were responders to checkpoint inhibitors, all responders to mTOR inhibitors were responders to checkpoint inhibitors

Article Snippet: Expression of phosphorylated-mTOR (p-mTOR) was examined by using anti-p-mTOR rabbit monoclonal antibody (clone 49F9) from Cell Signaling Technology, and Ventana BenchMark XT automatic immunostainer systems.

Techniques: Expressing

Journal: Archives of biochemistry and biophysics

Article Title: Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet

doi: 10.1016/j.abb.2015.11.040

Figure Lengend Snippet: Antibodies used in western blot.

Article Snippet: Anti-p-Torc2-Ser171 , BS-3415R , Bioss.

Techniques: Western Blot

Journal: Archives of biochemistry and biophysics

Article Title: Keap1/Nrf2 pathway activation leads to a repressed hepatic gluconeogenic and lipogenic program in mice on a high-fat diet

doi: 10.1016/j.abb.2015.11.040

Figure Lengend Snippet: A. Immunoblotting analysis of p-Ampkα-Thr172, total Ampkα, p-Ampkβ1-Ser108, total Ampkβ1 show that Ampk is activated in the Keap1-hypo mice after 90 days on HFD. Downstream targets of Ampk, Torc2 and Acc1 show increased phosphorylation at Ser171 and Ser79 correspondingly. Total Acc1 levels are lower in the Keap1-hypo mice.

Article Snippet: Anti-p-Torc2-Ser171 , BS-3415R , Bioss.

Techniques: Western Blot